@article{RietjensDussortGuentheretal.2018,
  author    = {Rietjens, Ivonne M. C. M. and Dussort, P. and G{\"u}nther, Helmut and Hanlon, Paul and Honda, Hiroshi and Mally, Angela and O'Hagan, Sue and Scholz, Gabriele and Seidel, Albrecht and Swenberg, James and Teeguarden, Justin and Eisenbrand, Gerhard},
  title     = {Exposure assessment of process-related contaminants in food by biomarker monitoring},
  series = {Archives of Toxicology},
  volume    = {92},
  journal   = {Archives of Toxicology},
  number    = {1},
  doi       = {10.1007/s00204-017-2143-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226268},
  pages     = {15-40},
  year      = {2018},
  abstract  = {Exposure assessment is a fundamental part of the risk assessment paradigm, but can often present a number of challenges and uncertainties. This is especially the case for process contaminants formed during the processing, e.g. heating of food, since they are in part highly reactive and/or volatile, thus making exposure assessment by analysing contents in food unreliable. New approaches are therefore required to accurately assess consumer exposure and thus better inform the risk assessment. Such novel approaches may include the use of biomarkers, physiologically based kinetic (PBK) modelling-facilitated reverse dosimetry, and/or duplicate diet studies. This review focuses on the state of the art with respect to the use of biomarkers of exposure for the process contaminants acrylamide, 3-MCPD esters, glycidyl esters, furan and acrolein. From the overview presented, it becomes clear that the field of assessing human exposure to process-related contaminants in food by biomarker monitoring is promising and strongly developing. The current state of the art as well as the existing data gaps and challenges for the future were defined. They include (1) using PBK modelling and duplicate diet studies to establish, preferably in humans, correlations between external exposure and biomarkers; (2) elucidation of the possible endogenous formation of the process-related contaminants and the resulting biomarker levels; (3) the influence of inter-individual variations and how to include that in the biomarker-based exposure predictions; (4) the correction for confounding factors; (5) the value of the different biomarkers in relation to exposure scenario's and risk assessment, and (6) the possibilities of novel methodologies. In spite of these challenges it can be concluded that biomarker-based exposure assessment provides a unique opportunity to more accurately assess consumer exposure to process-related contaminants in food and thus to better inform risk assessment.},
  language  = {en}
}
@article{SchmidbauerFerseSalihetal.2022,
  author    = {Schmidbauer, Moritz L. and Ferse, Caroline and Salih, Farid and Klingner, Carsten and Musleh, Rita and Kunst, Stefan and Wittstock, Matthias and Neumann, Bernhard and Schebesch, Karl-Michael and B{\"o}sel, Julian and Godau, Jana and Lochner, Piergiorgio and Adam, Elisabeth H. and Jahnke, Kolja and Knier, Benjamin and Schirotzek, Ingo and M{\"u}llges, Wolfgang and Notz, Quirin and Dengl, Markus and G{\"u}ldner, Andreas and Onur, Oezguer A. and Garcia Borrega, Jorge and Dimitriadis, Konstantinos and G{\"u}nther, Albrecht},
  title     = {COVID-19 and intracranial hemorrhage: a multicenter case series, systematic review and pooled analysis},
  series = {Journal of Clinical Medicine},
  volume    = {11},
  journal   = {Journal of Clinical Medicine},
  number    = {3},
  issn      = {2077-0383},
  doi       = {10.3390/jcm11030605},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-255236},
  year      = {2022},
  abstract  = {Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) profoundly impacts hemostasis and microvasculature. In the light of the dilemma between thromboembolic and hemorrhagic complications, in the present paper, we systematically investigate the prevalence, mortality, radiological subtypes, and clinical characteristics of intracranial hemorrhage (ICH) in coronavirus disease (COVID-19) patients. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review of the literature by screening the PubMed database and included patients diagnosed with COVID-19 and concomitant ICH. We performed a pooled analysis, including a prospectively collected cohort of critically ill COVID-19 patients with ICH, as part of the PANDEMIC registry (Pooled Analysis of Neurologic Disorders Manifesting in Intensive Care of COVID-19). Results: Our literature review revealed a total of 217 citations. After the selection process, 79 studies and a total of 477 patients were included. The median age was 58.8 years. A total of 23.3\% of patients experienced the critical stage of COVID-19, 62.7\% of patients were on anticoagulation and 27.5\% of the patients received ECMO. The prevalence of ICH was at 0.85\% and the mortality at 52.18\%, respectively. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.},
  language  = {en}
}
@article{VollmuthMuljukovAbuMugheisibetal.2021,
  author    = {Vollmuth, Christoph and Muljukov, Olga and Abu-Mugheisib, Mazen and Angermeier, Anselm and Barlinn, Jessica and Busetto, Loraine and Grau, Armin J. and G{\"u}nther, Albrecht and Gumbinger, Christoph and Hubert, Nikolai and H{\"u}ttemann, Katrin and Klingner, Carsten and Naumann, Markus and Palm, Frederick and Remi, Jan and R{\"u}cker, Viktoria and Schessl, Joachim and Schlachetzki, Felix and Schuppner, Ramona and Schwab, Stefan and Schwartz, Andreas and Trommer, Adrian and Urbanek, Christian and Volbers, Bastian and Weber, Joachim and Wojciechowski, Claudia and Worthmann, Hans and Zickler, Philipp and Heuschmann, Peter U. and Haeusler, Karl Georg and Hubert, Gordian Jan},
  title     = {Impact of the coronavirus disease 2019 pandemic on stroke teleconsultations in Germany in the first half of 2020},
  series = {European Journal of Neurology},
  volume    = {28},
  journal   = {European Journal of Neurology},
  number    = {10},
  doi       = {10.1111/ene.14787},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259396},
  pages     = {3267-3278},
  year      = {2021},
  abstract  = {Background and purpose The effects of the coronavirus disease 2019 (COVID-19) pandemic on telemedical care have not been described on a national level. Thus, we investigated the medical stroke treatment situation before, during, and after the first lockdown in Germany. Methods In this nationwide, multicenter study, data from 14 telemedical networks including 31 network centers and 155 spoke hospitals covering large parts of Germany were analyzed regarding patients' characteristics, stroke type/severity, and acute stroke treatment. A survey focusing on potential shortcomings of in-hospital and (telemedical) stroke care during the pandemic was conducted. Results Between January 2018 and June 2020, 67,033 telemedical consultations and 38,895 telemedical stroke consultations were conducted. A significant decline of telemedical (p < 0.001) and telemedical stroke consultations (p < 0.001) during the lockdown in March/April 2020 and a reciprocal increase after relaxation of COVID-19 measures in May/June 2020 were observed. Compared to 2018-2019, neither stroke patients' age (p = 0.38), gender (p = 0.44), nor severity of ischemic stroke (p = 0.32) differed in March/April 2020. Whereas the proportion of ischemic stroke patients for whom endovascular treatment (14.3\% vs. 14.6\%; p = 0.85) was recommended remained stable, there was a nonsignificant trend toward a lower proportion of recommendation of intravenous thrombolysis during the lockdown (19.0\% vs. 22.1\%; p = 0.052). Despite the majority of participating network centers treating patients with COVID-19, there were no relevant shortcomings reported regarding in-hospital stroke treatment or telemedical stroke care. Conclusions Telemedical stroke care in Germany was able to provide full service despite the COVID-19 pandemic, but telemedical consultations declined abruptly during the lockdown period and normalized after relaxation of COVID-19 measures in Germany.},
  language  = {en}
}
@article{JanzZinkCirnuetal.2021,
  author    = {Janz, Anna and Zink, Miriam and Cirnu, Alexandra and Hartleb, Annika and Albrecht, Christina and Rost, Simone and Klopocki, Eva and G{\"u}nther, Katharina and Edenhofer, Frank and Erg{\"u}n, S{\"u}leyman and Gerull, Brenda},
  title     = {CRISPR/Cas9-edited PKP2 knock-out (JMUi001-A-2) and DSG2 knock-out (JMUi001-A-3) iPSC lines as an isogenic human model system for arrhythmogenic cardiomyopathy (ACM)},
  series = {Stem Cell Research},
  volume    = {53},
  journal   = {Stem Cell Research},
  doi       = {10.1016/j.scr.2021.102256},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259846},
  pages     = {102256},
  year      = {2021},
  abstract  = {Arrhythmogenic cardiomyopathy (ACM) is characterized by fibro-fatty replacement of the myocardium, heart failure and life-threatening ventricular arrhythmias. Causal mutations were identified in genes encoding for proteins of the desmosomes, predominantly plakophilin-2 (PKP2) and desmoglein-2 (DSG2). We generated gene-edited knock-out iPSC lines for PKP2 (JMUi001-A-2) and DSG2 (JMUi001-A-3) using the CRISPR/Cas9 system in a healthy control iPSC background (JMUi001A). Stem cell-like morphology, robust expression of pluripotency markers, embryoid body formation and normal karyotypes confirmed the generation of high quality iPSCs to provide a novel isogenic human in vitro model system mimicking ACM when differentiated into cardiomyocytes.},
  language  = {en}
}